EGFR and non-small cell lung carcinoma: Notably, mutations in EGFR tyrosine kinases are pivotal in NSCLC progression,45 establishing inhibitors targeting EGFR tyrosine kinase as the primary treatment for NSCLC carrying EGFR exon 19 deletion or exon 21 mutation.25